Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583903 · ClinicalTrials.gov registry record · NA
Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention
A NA study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05583903: Completed NA study, sponsored by The Methodist Hospital Research Institute.
NCT05583903 is a NA study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05583903, a NA study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study aims to determine feasibility, acceptability, and usability, and to assess the safety of using a virtual reality-based software called ''ReCognitionVR'' in healthy volunteers.
Primary Outcome
Whether 70% of participants in each group will complete 20 minutes of use of the ReCognition VR-based software (a binary outcome)
Interventions
- OTHER Virtual Reality Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-08-14 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
What the finished NCT05583903 record still lists
NCT05583903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Virtual Reality Software is the first listed.
NCT05583903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05583903 about?
NCT05583903 is a clinical study titled "Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention". This study aims to determine feasibility, acceptability, and usability, and to assess the safety of using a virtual reality-based software called ''ReCognitionVR'' in healthy volunteers.
What is the current status of trial NCT05583903?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2022-08-14. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05583903?
The interventions under investigation include: Virtual Reality Software (OTHER).
Who is sponsoring clinical trial NCT05583903?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05583903's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI